newsfilter
← Latest News
GlobeNewswire·

BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting

BIVI
  • BioVie Inc. announced two abstracts from its ADDRESS-LC (Long COVID) & SUNRISE-PD (Parkinson's Disease) Phase 2 trials accepted for presentation at ANA2026 in San Diego, CA.
  • The ADDRESS-LC poster presentation is scheduled for Sunday, October 18, 2026, from 5:30–7:00 PM.
  • The SUNRISE-PD poster presentation is scheduled for Monday, October 19, 2026, from 5:30–7:00 PM.
  • Both studies utilize bezisterim (NE3107), an investigational oral drug that crosses the blood-brain barrier to reduce inflammation & improve insulin sensitivity.
  • The SUNRISE-PD trial enrolled 57 early-stage Parkinson's patients & showed bezisterim treatment led to improvements in inflammatory markers, cellular health biomarkers, & daily functioning compared to placebo.
  • The ADDRESS-LC trial enrolled approximately 200 Long COVID patients to evaluate bezisterim's effect on brain fog & fatigue, targeting persistent inflammation via NFκB activation.
  • The ADDRESS-LC trial did not achieve statistical significance on primary endpoints in the overall population; significant results were observed only in pre-specified subgroup analyses.
  • BioVie is also advancing BIV201, a terlipressin infusion for advanced liver disease, which has received FDA Orphan & Fast Track designations & plans to initiate a Phase 3 trial.
  • Forward-looking statements warn that clinical endpoints are exploratory, subgroup analyses may not replicate in future trials, & the FDA has not validated these endpoints as surrogates for Long COVID.